Ence S. Charles's most recent trade in Relmada Therapeutics Inc was a trade of 400,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Relmada Therapeutics Inc | Charles S. Ence | CA and CO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Charles S. Ence | CA and CO | Purchase of securities on an exchange or from another person at price $ 0.45 per share. | 16 May 2025 | 228,961 | 267,931 (1%) | 1% | 0.5 | 103,330 | Common Stock |
| Relmada Therapeutics Inc | Charles S. Ence | CA and CO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 54,624 | 136,714 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Charles S. Ence | CA and CO | Other type of transaction at price $ 0.00 per share. | 24 May 2024 | 54,624 | 82,090 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Ence Charles S. | CA and CO | Purchase of securities on an exchange or from another person at price $ 3.87 per share. | 29 Jan 2024 | 14,500 | 25,300 (0%) | 0% | 3.9 | 56,053 | Common Stock |
| Relmada Therapeutics Inc | Charles S. Ence | CA and CO | Purchase of securities on an exchange or from another person at price $ 4.05 per share. | 29 Jan 2024 | 13,670 | 38,970 (0%) | 0% | 4.1 | 55,429 | Common Stock |
| Relmada Therapeutics Inc | Charles Ence S. | CA and CO | Purchase of securities on an exchange or from another person at price $ 3.65 per share. | 29 Jan 2024 | 10,800 | 10,800 (0%) | 0% | 3.7 | 39,438 | Common Stock |
| Relmada Therapeutics Inc | Ence S. Charles | Chief Accounting and CO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2023 | 82,090 | 82,090 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Charles S. Ence | CA and CO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 321,238 | 518,361 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Charles S. Ence | CA and Compliance Officer | Other type of transaction at price $ 0.00 per share. | 16 Dec 2022 | 200,000 | 0 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Charles S. Ence | CA and CO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 197,123 | 197,123 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Charles S. Ence | CAO and Compliance Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2021 | 226,832 | 226,832 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Charles S. Ence | Chief Compliance Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2021 | 112,500 | 112,500 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Charles S. Ence | Chief Compliance Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2021 | 112,500 | 112,500 | - | - | Options to purchase common stock |